一、公司整体表现与战略转型四环医药在2025年上半年实现收入同比增长21%至11.5亿元,归母利润同比大增407%至1.0亿元。公司正处于从传统仿制药向“医美+创新药”双轮驱动的战略转型期。尽管仿制药业务受到国家政策影响而有所下滑,但医美和创新药板块的高速增长为公司带来了新的增长动力。二、医美板块:核心 驱动力医美业务是四环医药当前的核心增长引擎,2025年上半年医美收入同比增加81%至5.9亿元...
Source Link一、公司整体表现与战略转型四环医药在2025年上半年实现收入同比增长21%至11.5亿元,归母利润同比大增407%至1.0亿元。公司正处于从传统仿制药向“医美+创新药”双轮驱动的战略转型期。尽管仿制药业务受到国家政策影响而有所下滑,但医美和创新药板块的高速增长为公司带来了新的增长动力。二、医美板块:核心 驱动力医美业务是四环医药当前的核心增长引擎,2025年上半年医美收入同比增加81%至5.9亿元...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.